ARQT Arcutis Biotherapeutics
- 8.020
- +0.030+0.38%
- 8.024
- +0.004+0.05%
Arcutis Biotherapeutics News
Arcutis Biotherapeutics(ARQT.US) Officer Sells US$40,901.64 in Common Stock
$Arcutis Biotherapeutics(ARQT.US)$ Officer Moore Matthew Richard sold 4,681 shares of common stock on May 2, 2024 at an average price of $8.7378 for a total value of $40,901.64.Source: Announcement Wh
Form 144 | Arcutis Biotherapeutics(ARQT.US) Officer Proposes to Sell 120.43K in Common Stocks
SEC FILLINGS DISCLOSED/ May 2, $Arcutis Biotherapeutics(ARQT.US)$ Officer Watanabe Todd Franklin intends to sell 13,783 shares of its common stock on May 2, with a total market value of approximately
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Shareholders in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The consensus estimated reven
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $16 Price Target
Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $16 price target.
Arcutis Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/12/2024 34.57% Needham → $16 Reiterates Buy → Buy 02/28/2024 -7.49% Goldman Sachs $6 → $11 Maintains Ne
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)
Arcutis Biotherapeutics Welcomes New CFO David Topper
Arcutis Biotherapeutics Appoints CFO
Arcutis Biotherapeutics: Smither Will Remain to End of April to Ensure Smooth Transition >ARQT
Arcutis Biotherapeutics: Smither Will Remain to End of April to Ensure Smooth Transition >ARQT
Arcutis Biotherapeutics: Topper Replaces Interim CFO John Smither >ARQT
Arcutis Biotherapeutics: Topper Replaces Interim CFO John Smither >ARQT
Press Release: Arcutis Appoints David Topper as Chief Financial Officer
Arcutis Appoints David Topper as Chief Financial Officer Industry veteran with over 40 years of experience in finance, investment management, and investment banking WESTLAKE VILLAGE, Calif., April 1
Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Arcutis Biotherapeutics (ARQT)
Buy Rating on Arcutis Biotherapeutics Bolstered by Projected Q1 Sales Beat and 2024 Upside Potential
Sol-Gel's Collaboration Partner First-To-File ANDA Drug Product Generic To Zoryve Cream Indicated For Plaque Psoriasis In Patients Six Years Of Age And Older
On March 26, 2024, Arcutis Biotherapeutics initiated a patent infringement action in the U.S. District Court for the District of New Jersey regarding the Padagis Roflumilast Cream, 0.3% ANDA
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
WESTLAKE VILLAGE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), Arcutis Biotherapeutics (ARQT) and Axsome Therapeutics (AXSM)
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
Analysis
Price Target
No Data
